Allergan throws hat in the ring as Takeda and Shire confirm talks

19 April 2018
mergers-acquisitions-big

On the day that Takeda  Pharmaceutical (TYO: 4502) and Shire (LSE: SHP) confirmed that they had been in talks about the Japanese company’s proposals to take over the rare disease specialist, Ireland-incorporated drugmaker Allergan (NYSE: AGN) has put out a statement saying that it too is weighing up a bid.

Takeda’s interest in buying Shire first emerged last month, with the Osaka-based company saying that the deal would ‘create a truly global, value-based Japanese biopharmaceutical leader.’

In new statements, both companies have revealed details of talks that have taken place between them. There have been three offers made, worth between £41 billion ($58 billion) and £44 billion, and giving Shire shareholders ownership of between 50% and 51% of the enlarged Takeda.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical